The Technical Analyst
Aduro Biotech Inc [KDNY]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Aduro Biotech Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.22% $40.39
America/New_York / 10 aug 2023 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 2 708.13 mill |
| EPS: | -3.24 |
| P/E: | -12.47 |
| Earnings Date: | Nov 08, 2023 |
| SharesOutstanding: | 67.05 mill |
| Avg Daily Volume: | 2.04 mill |
| RATING 2023-08-18 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/22 | 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -12.47 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -2.12x |
| Company: PE -12.47 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 39.94 - 40.84 ( +/- 1.12%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-08-11 | Thomas Dolca | Sell | 13 300 | Common Stock |
| 2023-08-11 | Thomas Dolca | Sell | 23 522 | Stock Option (Right to Buy) |
| 2023-08-11 | Thomas Dolca | Sell | 5 948 | Stock Option (Right to Buy) |
| 2023-08-11 | Thomas Dolca | Sell | 13 300 | Stock Option (Right to Buy) |
| 2023-08-11 | Oxtoby Andrew | Sell | 160 000 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| -95.98 |
| Last 99 transactions |
| Buy: 289 232 | Sell: 10 194 260 |
Forecast:
01:40 - $43.57
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $40.39 (0.22% ) |
| Volume | 3.28 mill |
| Avg. Vol. | 2.04 mill |
| % of Avg. Vol | 160.49 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For KDNY
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
KDNY
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington.
Latest Press Releases
2023-08-18 05:00:00 - Press Release
Investigation Alert: The Schall Law Firm Announces It Is Investigating Claims Against Chinook Therapeutics, Inc. And Encourages Investors With Losses To Contact The Firm
Los angeles, ca / accesswire / august 18, 2023 / the schall law firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of chinook therapeutics, inc. ("chinook" or "the company") (nasdaq:kdny) for violations of the securities laws. the investigation focuses on whether the company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
2023-08-11 11:30:00 - Press Release
Novartis Completes Acquisition Of Chinook Therapeutics
Basel, august 11, 2023 — novartis today announced that it has completed its acquisition of chinook therapeutics, inc., a seattle, wa, based biopharmaceutical company focused on the discovery, development, and commercialization of precision medicines for kidney diseases, in a transaction valued at up to usd 3.5 billion.
2023-08-05 07:00:00 - Press Release
Investor Action Alert: The Schall Law Firm Announces It Is Investigating Claims Against Chinook Therapeutics, Inc. And Encourages Investors With Losses To Contact The Firm
Los angeles, ca / accesswire / august 5, 2023 / the schall law firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of chinook therapeutics, inc. ("chinook" or "the company") (nasdaq: kdny) for violations of the securities laws. the investigation focuses on whether the company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
2023-08-04 05:00:00 - Press Release
Investigation Alert: The Schall Law Firm Announces It Is Investigating Claims Against Chinook Therapeutics, Inc. And Encourages Investors With Losses To Contact The Firm
Los angeles, ca / accesswire / august 4, 2023 / the schall law firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of chinook therapeutics, inc. ("chinook" or "the company") (nasdaq:kdny) for violations of the securities laws. the investigation focuses on whether the company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
2023-08-03 05:00:00 - Press Release
Investor Action Alert: The Schall Law Firm Announces It Is Investigating Claims Against Chinook Therapeutics, Inc. And Encourages Investors With Losses To Contact The Firm
Los angeles, ca / accesswire / august 3, 2023 / the schall law firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of chinook therapeutics, inc. ("chinook" or "the company") (nasdaq:kdny) for violations of the securities laws. the investigation focuses on whether the company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Latest News
2023-08-02 12:01:36 - GuruFocus
Chief Scientific Officer Andrew King Sells 1,168 Shares of Chinook Therapeutics Inc (KDNY)
On August 1, 2023, Andrew King, the Chief Scientific Officer of Chinook Therapeutics Inc ( KDNY , Financial), sold 1,168 shares of the company. This move is part of a series of insider transactions that have taken place over the past year.
2023-06-20 09:33:57 - The Motley Fool
2 Surging Healthcare Stocks With More Fuel in the Tank
Shares of two biotech stocks are way up over the past month thanks to impressive clinical trial results for the drugs they're developing. Chinook Therapeutics has agreed to a buyout offer from Merck but the stock is still below the offered price.
2023-06-13 08:05:01 - MarketBeat
Novartis Stock Screams Value After Chinook Therapeutics Buyout
That value proposition took a huge step forward on Monday when Novartis announced a $3.2 billion acquisition of Seattle-based biotechnology company Chinook Therapeutics. A specialist in the development of precision medicines for chronic kidney diseases, Chinook Therapeutics becomes the latest addition to Novartis' expanding innovative medicines portfolio.
2023-06-12 16:40:50 - InvestorPlace
KDNY Stock Alert: Why Short Seller Muddy Waters Is Betting Against Chinook
Chinook Therapeutics (NASDAQ: KDNY ) has been surging all day. Why? KDNY stock surged on news that multinational pharmaceutical giant Novartis (NYSE: NVS ) will acquire the firm, which is known for kidney care and treatment.
2023-06-12 16:00:00 - GlobeNewsWire
Chinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) Congress
SEATTLE, June 12, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced a focused oral presentation on zigakibart (BION-1301) will be presented on Friday, June 16, 2023 at the 60th ERA Congress being held virtually and live in Milan, Italy.
2023-06-12 15:40:00 - Market Watch
Novartis deal for Chinook makes kidney-treatment competitors more attractive, analysts say
In light of a Novartis NVS, -0.94% deal to acquire Chinook Therapeutics Inc. KDNY, +58.09%, which is developing treatments for a rare kidney disease, two other companies focused on the same disease look even more attractive, analysts said Monday.
2023-06-12 12:51:14 - The Motley Fool
Why Shares of Chinook Therapeutics Skyrocketed On Monday
Novartis has agreed to buy out Chinook in a deal that could be worth $3.5 billion. Chinook is a clinical-stage biotech.
2023-06-12 12:10:38 - Investopedia
Chinook Therapeutics Shares Soar on Novartis Purchase
2023-06-12 10:23:51 - Proactive Investors
Novartis makes Chinook Therapeutics $3.2B offer
Chinook Therapeutics, Inc stock surged by more than half in early trade after the company said it agreed to a $40 per share buyout offer by Novartis AG (ADR) (NYSE:NVS). The $3.2 billion offer represents a 67% premium to Chinook's closing price on Friday, May 9, and is 83% higher than the 60-day volume-weighted average price of its shares.
2023-06-12 08:55:23 - InvestorPlace
Why Is Chinook Therapeutics (KDNY) Stock Up 58% Today?
Chinook Therapeutics (NASDAQ: KDNY ) stock is rocketing higher on Monday after the company announced it's being acquired by Novartis AG (NYSE: NVS ). Novartis AG is acquiring Chinook Therapeutics in a $3.2 billion deal.